Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal

Fineline Cube Dec 23, 2025
Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Policy / Regulatory

CDE Reference Standards 101st Batch Seeks Public Feedback

Fineline Cube Dec 23, 2025
Company Drug

Aosaikang’s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections

Fineline Cube Dec 23, 2025
Company Drug

3SBio’s rhTPO Wins NMPA Approval for Liver Disease Thrombocytopenia Before Surgery

Fineline Cube Dec 23, 2025
Policy / Regulatory

China’s Health Commission Promotes Medical-Elderly Care Integration

Fineline Cube Aug 24, 2022

China’s National Health Commission (NHC), National Development and Reform Commission (NDRC), and National Healthcare Security...

Policy / Regulatory

China Passes WHO NRA Evaluation for Vaccine Regulatory System

Fineline Cube Aug 24, 2022

The World Health Organization (WHO) announced that China has successfully passed the evaluation of its...

Company Drug

SinoMab Bioscience’s SN1011 Gets NMPA Nod for NMOSD Trial

Fineline Cube Aug 24, 2022

Hong Kong-based SinoMab Bioscience Ltd (HKG: 3681) has received approval from the National Medical Products...

Company Drug

Mabwell Bioscience Receives NMPA Approval for 6MW3511 Clinical Trial in Solid Tumors

Fineline Cube Aug 24, 2022

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that the National Medical Products Administration...

Company Drug

Bio-Thera Solutions Receives NMPA Approval for BAT8008 Clinical Trial in Solid Tumors

Fineline Cube Aug 24, 2022

Bio-Thera Solutions (SHA: 688177), a Guangzhou-based biotech firm, has received approval from the National Medical...

Company Drug

BeiGene’s Tislelizumab Receives 11th NMPA Filing for First-Line Esophageal Cancer

Fineline Cube Aug 24, 2022

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced that the National Medical Products Administration (NMPA)...

Company Drug

Innovent Biologics Doses First Patient in Australia Trial for PD-1/IL-2 Bispecific Antibody IBI363

Fineline Cube Aug 24, 2022

China-based Innovent Biologics, Inc. (HKG: 1801) announced that the first patient has been dosed in...

Company Deals

Lee’s Pharma Expands Global Rights to Windtree’s KL4 Surfactant Products

Fineline Cube Aug 24, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has expanded its licensing agreement with US-based Windtree...

Company Deals

Genetron Holdings Receives Buyout Offer from CEO Wang Sizhen at USD 1.36 per ADS

Fineline Cube Aug 24, 2022

Beijing-based precision oncology firm Genetron Holdings Ltd announced receipt of a buyout and take-private offer...

Drug Legal / IP

Supreme People’s Court Rules Against Chugai in China’s First Patent Linkage Case

Fineline Cube Aug 24, 2022

China’s Supreme People’s Court has delivered its verdict in the nation’s first patent linkage dispute,...

Company

Ascletis Pharma’s H1 2022 Revenue Rises 4.8% on R&D and Product Sales Growth

Fineline Cube Aug 23, 2022

Ascletis Pharma Inc. (HKG: 1672) reported RMB 38.2 million (USD 5.96 million) in revenue for...

Company Drug

Viatris Pharmaceuticals’ HIV/AIDS Drug Prioritized for CDE Review

Fineline Cube Aug 23, 2022

The Center for Drug Evaluation (CDE) has indicated that Viatris Pharmaceuticals Co., Ltd’s efavirenz/lamivudine/tenofovir is...

Company Deals

Hansoh Pharma Licenses GHDDI’s GDI-4405 for Global Development in COVID-19

Fineline Cube Aug 23, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced a licensing agreement with the Global...

Company Drug

Anhui Anke’s HK010 Bispecific Antibody Receives NMPA Review for Cancer Trials

Fineline Cube Aug 23, 2022

Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that the National Medical Products Administration...

Company Deals

China-Based Firms Form Partnership to Advance Cell and Gene Therapy Ecosystem

Fineline Cube Aug 23, 2022

Six China-based companies—Porton Advanced Solutions Ltd, Shanghai Sequanta Biological Technology Co., Ltd, QuaCell Biotechnology Co.,...

Company Deals

BIOPSEE Series A+ Financing Confocal Microendoscope

Fineline Cube Aug 23, 2022

BIOPSEE, a Hubei-based microendoscope specialist, has raised tens of millions of renminbi in a Series...

Company Drug

CSPC Pharmaceutical’s DBPR108 Hits Endpoints in Type 2 Diabetes Trials

Fineline Cube Aug 23, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its Category 1 drug DBPR108 has...

Company Drug

Shanghai Pharmaceuticals Gets NMPA Approval for B013 in Triple-Negative Breast Cancer

Fineline Cube Aug 23, 2022

Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has received approval from the National Medical Products Administration...

Company Drug

Scitop Bio-tech’s KEX02 Live Bacteria Therapy Gets FDA IND Approval for NSCLC

Fineline Cube Aug 23, 2022

Beijing Scitop Bio-tech Co., Ltd (SHE: 300858) announced that the US Food and Drug Administration...

Company Deals

Sanyou Biopharmaceuticals and KangaBio Ink Licensing Deal for Antibody Drug Candidate

Fineline Cube Aug 22, 2022

Shanghai-based Sanyou Biopharmaceuticals Co., Ltd and KangaBio have entered into a licensing agreement, granting Kanga...

Posts pagination

1 … 568 569 570 … 601

Recent updates

  • Aosaikang’s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections
  • Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal
  • 3SBio’s rhTPO Wins NMPA Approval for Liver Disease Thrombocytopenia Before Surgery
  • Gilead’s Seladelpar Wins China Hainan Approval for PBC Treatment
  • Alphamab JSKN003 ADC FDA Breakthrough Therapy Targets Ovarian Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Aosaikang’s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections

Company Deals

Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal

Company Drug

3SBio’s rhTPO Wins NMPA Approval for Liver Disease Thrombocytopenia Before Surgery

Company Drug

Gilead’s Seladelpar Wins China Hainan Approval for PBC Treatment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.